MELVILLE, N.Y., May 27, 2015 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or "the Company") (OTCQB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that Francisco Silva, Vice President of Research and Development and Chief Scientist, will present data from the Company's ongoing programs to develop a human-derived 3D brown adipose tissue construct at the 21st Annual Meeting of the International Society for Cellular Therapy (ISCT). The meeting will take place in Las Vegas from May 27th through May 30th.
Data presented will detail the development of BioRestorative's ThermoStem® program, which uses brown adipose derived stem cells as a platform for the development of 3D brown adipose tissue contructs that can be used for the treatment of metabolic disorders such as obesity and type 2 diabetes.
"We are pleased to present the progress of our ThermoStem® program that demonstrates the use of BioRestorative's proprietary cell-based technology for developing novel 3D engineered tissue constructs. We believe that this platform technology represents a potential breakthrough therapy for obesity and other metabolic disorders as a result of the demonstrated ability to generate brown adipose tissue using brown adipose derived stem cells. We look forward to sharing the details of the program's progress with key members of the cell therapy community, and to further assessing the potential of ThermoStem®," said Mark Weinreb, the company's CEO.
Additional information about the 21st Annual Meeting of the International Society for Cellular Therapy is available at: http://www.isct2015.com.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program: Our lead cell therapy candidate, brtxDISC™ (Disc Implanted Stem Cells), is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The treatment involves collecting a patient's own stem cells, culturing and cryopreserving the cells, and then having a physician inject brtxDISC™ into the patient's damaged disc in an outpatient procedure. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
• Metabolic Program (ThermoStem®): We are developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.